AHEP1531: Hepatoblastoma in Children & Young Adults

What is the Purpose of this Study?

If you choose to join this study, you will:
- Get treatments based on the group you are assigned

-- Group A: patients with very low risk disease
-- Group B: patients with low risk disease
-- Group C: patients with intermediate risk disease
-- Group D: patients with high risk disease

Depending on your assigned group, you may:
-- Get chemotherapy drugs such as cisplatin, doxorubicin, fluorouracil, vincristine sulfate, carboplatin, etoposide, irinotecan, sorafenib, gemcitabine and/or oxaliplatin.
--- Be randomized (like flipping a coin) to different types or doses of chemotherapy
-- Have surgery to remove your tumor
What is the Condition Being Studied?
Children and young adults with Hepatoblastoma

Who Can Participate in this Study?

Adults and children who:

- Are up to age 30

- Have a newly diagnosed primary pediatric hepatic malignancy

Age Group
Both
Participating Institutions

What is Involved?

We are doing this study to compare the effects (good and/or bad) of cisplatin with the combination of chemotherapy in treating children and young adults with hepatoblastoma or liver cancer after surgery.

Study Details

Full Title
AHEP1531: Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Principal Investigator

Contacts
Protocol Number
IRB:
PRO00101163

NCT:
NCT03533582
ClinicalTrials.gov
View on ClinicalTrials.gov